Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 8:00 am ET in Miami, FL. The presentation will be available via webcast on the company's investor relations website, with replay access for at least 30 days following the event.
Fulcrum Therapeutics (NASDAQ: FULC), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di piccole molecole per malattie genetiche rare, ha annunciato la sua partecipazione alla 46ª Conferenza Annuale Globale sulla Sanità di Goldman Sachs. Il management dell'azienda parteciperà a un incontro informale il 11 giugno 2025 alle 8:00 ET a Miami, FL. La presentazione sarà disponibile in webcast sul sito web delle relazioni con gli investitori dell'azienda, con accesso alla replica per almeno 30 giorni dopo l'evento.
Fulcrum Therapeutics (NASDAQ: FULC), una compañía biofarmacéutica en etapa clínica especializada en el desarrollo de pequeñas moléculas para enfermedades genéticas raras, ha anunciado su participación en la 46ª Conferencia Anual Global de Salud de Goldman Sachs. La dirección de la empresa participará en una charla informal el 11 de junio de 2025 a las 8:00 am ET en Miami, FL. La presentación estará disponible vía webcast en el sitio web de relaciones con inversionistas de la compañía, con acceso a la repetición durante al menos 30 días después del evento.
Fulcrum Therapeutics (NASDAQ: FULC)는 희귀 유전 질환을 위한 소분자 개발에 특화된 임상 단계의 바이오제약 회사로, 제46회 골드만 삭스 글로벌 헬스케어 연례 회의에 참여할 예정입니다. 회사 경영진은 2025년 6월 11일 오전 8시(동부시간) 플로리다 마이애미에서 진행되는 비공식 대화에 참여합니다. 발표 내용은 회사 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 행사 후 최소 30일간 다시보기 서비스를 이용할 수 있습니다.
Fulcrum Therapeutics (NASDAQ : FULC), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de petites molécules pour les maladies génétiques rares, a annoncé sa participation à la 46e conférence annuelle mondiale sur la santé de Goldman Sachs. La direction de la société participera à une discussion informelle le 11 juin 2025 à 8h00 ET à Miami, FL. La présentation sera accessible en webcast sur le site des relations investisseurs de la société, avec un accès au replay pendant au moins 30 jours après l'événement.
Fulcrum Therapeutics (NASDAQ: FULC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von niedermolekularen Wirkstoffen für seltene genetische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 46. jährlichen Goldman Sachs Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am 11. Juni 2025 um 8:00 Uhr ET in Miami, FL, an einem informellen Gespräch teilnehmen. Die Präsentation wird per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiederholungsansicht für mindestens 30 Tage nach der Veranstaltung.
- None.
- None.
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, FL on Wednesday, June 11, 2025 at 8:00 am ET.
The webcast of the fireside chat will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I access Fulcrum Therapeutics' (FULC) presentation at the Goldman Sachs Healthcare Conference?
What is Fulcrum Therapeutics' (FULC) main business focus?
How long will the replay of FULC's Goldman Sachs Conference presentation be available?
